Antineoplastic agents
People living with metastatic prostate cancer in England will gain access to a new treatment combination from today, following a recommendation by NICE. Darolutamide, also known as Nubeqa, is a medication that blocks the hormones fuelling cancer growth by starving prostate cancer cells of the testosterone they need to multiply
Diabetes therapy
Current research has shed light on the potential impact of tirzepatide, a dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) co-agonist, in treating type 2 diabetes and obesity. Studies have demonstrated that tirzepatide significantly reduces HbA1c levels and induces weight loss in diverse patient populations, with gastrointestinal
Class action lawsuits
Shareholders who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) during the period from December 27, 2023 to May 6, 2025 are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment in a class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding
Diseases
MapLight Therapeutics has initiated a Phase 2 study to evaluate the efficacy, safety, and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential treatment for Alzheimer's disease psychosis (ADP). The study, known as the VISTA study, has been designed based on the results of an
Diseases
South Korean biotech firm AppClone has achieved a significant milestone with its next-generation CAR-T therapy, 'Nespeseal (AT101)', receiving designation as a development-stage orphan drug by the Ministry of Food and Drug Safety. This designation provides AppClone with various benefits, including extended marketing authorization, simplified data submission, and exclusive
Diseases
Regeneron is quickly moving forward with FDA approval plans for its treatment garetosmab in fibrodysplasia ossificans progressiva (FOP) after a phase 3 clinical trial demonstrated a significant reduction in abnormal bone lesions. The study, which enrolled 63 adults with FOP, randomized patients to receive one of two doses of garetosmab
Diseases
Eisai has initiated a rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Leqembi Iqlik, a subcutaneous autoinjector for the treatment of Alzheimer's disease. This submission follows the approval of Leqembi Iqlik for maintenance dosing in the US
COVID-19
As the COVID-19 crisis has receded, the landscape of vaccination has changed, making it more complex for Illinoisans to navigate. With the federal government reducing access and Health Secretary Robert Kennedy Jr. casting doubt on vaccines, despite scientific evidence of their efficacy, new eligibility rules have been introduced. This has
COVID-19
California is experiencing a resurgence in COVID-19 cases, particularly due to the spread of the new LP.8.1 variant. In response, the US Food and Drug Administration has approved a revised COVID-19 vaccine developed by Pfizer and BioNTech, specifically designed to combat the emerging LP.8.1 subvariant. The
COVID-19
In the midst of confusion and apparent age restrictions at the federal level, several states are taking proactive steps to guarantee their residents have wide access to the COVID-19 vaccine this fall. The move comes in response to the Food and Drug Administration's recent approval of updated COVID-19
COVID-19
U.S. Rep. Buddy Carter, who is running for Senate, has come to the defense of Health and Human Services Secretary Robert F. Kennedy Jr. amid controversy over the new guidelines for COVID-19 vaccines. Despite the FDA's approval of updated COVID-19 shots for the fall, Kennedy's
Vaccines
The New Mexico Department of Health has issued a public health order to ensure access to COVID-19 vaccines at pharmacies across the state, responding to pharmacies' announcements that they cannot administer the vaccine without a recommendation from the Advisory Committee on Immunization Practices (ACIP). The order comes after the
